Skip to main
HUMA
HUMA logo

Humacyte (HUMA) Stock Forecast & Price Target

Humacyte (HUMA) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Humacyte Inc has demonstrated significant growth in sales, with approximately 29 units sold in the latest quarter compared to around 4 units in the previous quarter, indicating an increasing market traction for its Symvess product. The company has gained approvals from approximately 25 vascular access centers (VACs) and expanded access to around 92 civilian hospitals, showcasing the rising familiarity and acceptance of its technology among clinicians. Additionally, Humacyte's commitment to building a robust clinical evidence base, combined with effective manufacturing capabilities and potential non-dilutive financing opportunities, reinforces a positive outlook for future growth and scalability in the biotechnology sector.

Bears say

Humacyte Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from potential delays in clinical trial enrollment and product development, which could hinder timely market entry. The company also contends with numerous risks, including adverse clinical outcomes in ongoing trials and regulatory hurdles, that may impact its pipeline of innovative biotechnology products. Furthermore, the need for additional capital could lead to dilution and prolonged commercialization timelines that undermine investor confidence in the company’s future growth.

Humacyte (HUMA) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humacyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humacyte (HUMA) Forecast

Analysts have given Humacyte (HUMA) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Humacyte (HUMA) has a Strong Buy consensus rating as of Dec 18, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humacyte (HUMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.